Margaret Stanley (virologist)

From Wikipedia, the free encyclopedia

Margaret Anne Stanley, OBE FMedSc, is a British virologist and epithelial biologist. She attended the Universities of London, Bristol, and Adelaide.[1] As of 2018, she is an Emeritus Professor of Epithelial Biology in the Department of Pathology at the University of Cambridge and a Fellow of the Academy of Medical Sciences.[2] She is also an Honorary Fellow of the UK Royal College of Obstetricians and Gynaecologists and an honorary fellow of Christ's College, Cambridge.[3] Stanley is a research scientist in virology focusing on the human papillomavirus (HPV).[4] Her research work has led to new scientific findings on HPV. Additionally, she uses her expertise on HPV to serve on multiple advisory committees and journal editorial boards.[4]

Research[edit]

Stanley's main research interest is the pathogenesis of HPV, and she currently leads a research group focusing on the prevention and treatment of human papillomavirus infection, which causes cervical cancer.[5]

Early in her research, she generated a non-tumorigenic human cervical keratinocyte cell line, W12, from a low-grade cervical lesion. W12 cells can harbor HPV-16 episomes and thus allow researchers the ability to investigate the complex processes of cervical cancer development.[6] Additionally, she helped to discover the temporal association between high-level chromosomal instability and high-risk human papillomavirus (HR-HPV) integration, a key step in cervical carcinogenesis, such that integration precedes chromosomal abnormalities.[7]

She also studies the host cell responses to infection with the human papillomavirus in immunodeficient individualsimmunodeficient, most commonly HIV-positive immunosuppressant individuals.[8] Evidence from animal models shows that a CD4(+) T cell-dominated Th1 response leads to regression of anogenital warts, an effective cell-mediated immune response (CMI).[9] She states that a failure to produce this effective CMI response to the human papillomavirus facilitates viral persistence, and this can lead to the progression of high-grade disease and invasive cervical cancer.[10]

Career[edit]

From 2000 to 2003, she was a member of the Biotechnology and Biological Sciences Research Council (BBSRC). Since then, she has served on multiple UK Research Council committees. She has served on two of the Biotechnology and Biological Sciences Research Council's (BBSRC) major committees and its council for the past ten years. Since 1991, she has been a fellow at Christ's College.[citation needed]

From 2004 to 2010, she served on the Spongiform Encephalopathies Advisory Committee (SEAC).[4] Stanley's involvement in the SEAC was to provide independent scientific data to the UK government on transmissible spongiform encephalopathies (TSEs) and advise the government's public health, food safety, and animal health policies.

In 2017, Stanley was recruited by the American Society of Clinical Oncology to be on a multidisciplinary expert panel that presented new evidence-based recommendations for primary cervical cancer prevention.[11] The number of recommended dosages of the HPV vaccine varies based on resource availability, age, and sex. Stanley endorses the reduction of the recommended HPV vaccine dosage from 3 to 2 for children aged 14 and younger. Additionally, she states that there is preliminary evidence for the effectiveness of just one dosage of the HPV vaccine, and further research needs to be conducted.[12]

Currently, Stanley serves as an expert on HPV for the HPV subcommittee of the UK's Joint Committee on Vaccines and Immunization.[4] She also serves on the editorial board for the following scientific journals: Sexually Transmitted Infections, Journal of Clinical Virology, and Reviews in Medical Virology.[1] Stanley is also working as a consultant for companies that market HPV vaccines. Some of these companies include GSK, MSD, and Sanofi Pasteur MSD.[4] She also works with small biotech firms that are creating therapeutic vaccines.  She serves as the Joint Committee on Vaccines and Immunization in the UK's HPV subcommittee's invited HPV expert. [13]

Advocacy[edit]

Stanley is a vocal advocate of HPV vaccination pre-puberty, specifically between the ages of 13 and early 20s. Stanley acknowledges that the recommended HPV vaccines have been shown to generate high enough concentrations of antibodies to fight the virus.[14][15] Stanley also urges that both sexes be vaccinated because both are susceptible to HPV-related illnesses.[16][17] She endorses both licensed HPV L1 VLP vaccines, the bivalent vaccine for HPV types 16 and 18 (Cervarix) and the quadrivalent vaccine for HPV types 6, 11, 16, and 18 (Gardasil). Stanley states that both licensed HPV vaccines are safe and highly immunogenic.[18]

Stanley is currently the Vice President of the International Papillomavirus Society (IPVS) and a member of the IPVS's Executive, Policy, and Strategy and Planning Committees. Her main work with the IPVS is encouraging nations to endorse and utilize the readily available and effective HPV vaccinations to help prevent and treat HIV infection in young people.[4]

Awards and honors[edit]

In 2004, Stanley was awarded an OBE for services to virology.[19] In 2010, she was given the Lifetime Achievement Award by the American Society for Colposcopy and Cervical Pathology (ASCCP) for her contributions to cervical cancer and cervical precancers research.[20] She also holds a lifetime award for achievement from the International Papillomavirus Society.[21] In 2023, Stanley received the Maurice Hilleman Award from the International Papillomavirus Society.[22]

Key papers[edit]

References[edit]

  1. ^ a b "Margaret Stanley". Archived from the original on 27 April 2018. Retrieved 9 March 2018.
  2. ^ Academy of Medical Sciences: Fellows: Professor Margaret Stanley (accessed 6 January 2009)
  3. ^ Christ's College, University of Cambridge: Prof Margaret Anne Stanley[permanent dead link] (accessed 6 January 2009)
  4. ^ a b c d e f "Stanley, Margaret". International Papillomavirus Society. 2017. Retrieved 18 February 2018.
  5. ^ "Professor Margaret Stanley OBE". University of Cambridge. 25 March 2015. Retrieved 18 February 2018.
  6. ^ Stanley MA, Browne HM, Appleby M, & Minson AC (April 1989). "Properties of a non-tumorigenic human cervical keratinocyte cell line". International Journal of Cancer. 43 (4): 672–676. doi:10.1002/ijc.2910430422. PMID 2467886. S2CID 25064033.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ Pett; et al. (February 2004). "Acquisition of High-Level Chromosomal Instability Is Associated with Integration of Human Papillomavirus Type 16 in Cervical Keratinocytes". Cancer Research. 64 (4): 1359–1368. doi:10.1158/0008-5472.can-03-3214. PMID 14973079.
  8. ^ Stanley, MA, Sterling, JC (March 2014). "Host responses to infection with human papillomavirus". Current Problems in Dermatology. 45: 58–74. doi:10.1159/000355964. ISBN 978-3-318-02526-2. PMID 24643178.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ Stanley, Margaret (April 2012). "Epithelial cell responses to infection with human papillomavirus". Clinical Microbiology Reviews. 25 (2): 215–222. doi:10.1128/cmr.05028-11. PMC 3346303. PMID 22491770.
  10. ^ Stanley, Margaret (20 October 2010). "HPV - immune response to infection and vaccination". Infectious Agents and Cancer. 5 (1): 19. doi:10.1186/1750-9378-5-19. ISSN 1750-9378. PMC 3161350.
  11. ^ Arrossi; et al. (March 2017). "Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline". Journal of Global Oncology. 3 (5): 611–615. doi:10.1200/JGO.2016.008151. PMC 5646902. PMID 29094100.
  12. ^ Stanley, Margaret (July 2016). "Preventing cervical cancer and genital warts – How much protection is enough for HPV vaccines?". The Journal of Infection. 72 Supplemental: S23-28. doi:10.1016/j.jinf.2016.04.018. PMID 27211079.
  13. ^ "Stanley, Margaret". IPVS. Retrieved 8 October 2023.
  14. ^ “The development of vaccines and immunotherapies against human papillomaviruses, the cause of cervix cancer” event Nov. 2012 (Accessed 18 April 2016)
  15. ^ The Naked Scientist Interview May 2010 (Accessed 18 April 2016)
  16. ^ Brody, Herb (2012). "Human papillomavirus". Nature. 488 (7413): S1. Bibcode:2012Natur.488S...1B. doi:10.1038/488S1a. PMID 22932432.
  17. ^ Stanley, Margaret (2012). "Perspective: Vaccinate boys too". Nature. 488 (7413): S10. Bibcode:2012Natur.488S..10S. doi:10.1038/488S10a. PMID 22932433. S2CID 6458476.
  18. ^ Stanley, Margaret (September 2007). "Prophylactic HPV vaccines". Journal of Clinical Pathology. 60 (9): 961–965. doi:10.1136/jcp.2006.040568. PMC 1972442. PMID 17259297.
  19. ^ London Gazette (31 December 2003) Suppl. 1: S13
  20. ^ "2010 Lifetime Achievement Award Recipients". American Society for Colposcopy and Cervical Pathology. Archived from the original on 17 October 2012. Retrieved 8 November 2012.
  21. ^ "Professor Margaret Stanley OBE". University of Cambridge. 2017. Retrieved 18 February 2018.
  22. ^ "2023 Maurice Hilleman award". IPVS. Retrieved 17 September 2023.

[1]

External links[edit]

  1. ^ "Human Papillomavirus".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Margaret_Stanley_(virologist)&oldid=1209217739"